Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure in COVID-19

Maulin Patel MD¹, Andrew Gangemi MD¹, Robert Marron MD¹, Junad Chowdhury MD¹, Ibraheem Yousef MD¹, Matthew Zheng MD¹, Nicole Mills DO¹, Lauren Tragesser MS4², Julie Giurintano MS4², Rohit Gupta MD¹, Matthew Gordon MD¹, Parth Rali MD¹, Gilbert D'Alonzo, DO¹, David Fleece MD¹, Huaging Zhao, P hd², Nicole Patlakh BSc², and Gerard J. Criner MD¹ for the Temple University COVID-19 Research Group*

None of the authors have any conflict of interest related to the material discussed in this article

Contact Information Maulin Patel, MD Temple University Hospital, 7th floor Parkinson Pavilion 3401 N Broad St, Philadelphia, PA 19140 maulin.patel@tuhs.temple.edu Phone #: 2678582225

Author Contributions:

Maulin Patel, Gerard J Criner formulated the overall study design. Huaging Zhao, Nicole Patlakh, David Fleece, Maulin Patel, Andrew Gangemi, Robert Marron, Junad Chowdhury, Nicole Mills, Lauren Tragesser and Julie Tragesser assisted in data collection, consolidation and analysis. Maulin Patel, Andrew Gangemi, Robert Marron, Junad Chowdhury, Ibraheem Yousef, Matthew Zheng, Rohit Gupta, Matthew Gordon, Parth Rali and Gilbert D'Alonzao drafted the manuscript. Gerard J Criner revised and reviewed the Manuscript

Running head: HFNT in COVID-19 infection Key words: COVID-19, HFNT, respiratory failure

Summary

Abstract – 217

Text – 3353 words

References - 2036 words

Tables – 6

Figures - 5

¹ - Department of Thoracic Medicine and Surgery, Temple University Hospital

² – Lewis Katz School of Medicine at Temple University.

^{*-}see supplement

Key Points

Key Question: What is the utility of High Flow Nasal Therapy (HFNT) in COVID-19 related

Hypoxemic Respiratory Failure?

Bottom Line: In this retrospective analysis of moderate to severe hypoxic respiratory failure for

COVID 19 patients, 67 patients (65.4%) were able to avoid intubation despite severely low SF

ratio (Mean 121.9).

Why Read on: HFNT has a significant role in COVID-19 for reducing rate of intubations and

associated mortality

Abstract

Invasive mechanical has been associated with high mortality in COVID-19. Alternative therapy

of High flow nasal therapy (HFNT) has been greatly debated around the world for use in

COVID-19 pandemic due to concern for increased healthcare worker transmission.

Methods

This was a retrospective analysis of consecutive patients admitted to Temple University Hospital

in Philadelphia, Pennsylvania, from March 10, 2020, to April 24, 2020 with moderate to severe

respiratory failure treated with High Flow nasal therapy (HFNT). Primary outcome was

prevention of intubation.

Results

Of the 445 patients with COVID-19, 104 met our inclusion criteria. The average age was 60.66 (

2

+13.50) years, 49 (47.12 %) were female, 53 (50.96%) were African American, 23 (22.12%)

Hispanic. Forty-three patients (43.43%) were smokers. SF and chest Xray scores had a statistically significant improvement from day 1 to day 7. 67 of 104 (64.42%) were able to avoid invasive mechanical ventilation in our cohort. Incidence of hospital/ventilator associated pneumonia was 2.9%. Overall, mortality was 14.44% (n=15) in our cohort with 13 (34.4%) in the progressed to intubation group and 2 (2.9%) in the non-intubation group. Mortality and incidence of VAP/HAP was statistically higher in the progressed to intubation group.

Conclusion

HFNT use is associated with a reduction in the rate of Invasive mechanical ventilation and overall mortality in patients with COVID-19 infection.

Introduction

In December of 2019 a cluster of acute respiratory illnesses occurred in Hubei province, China, now known to be caused by a novel Coronavirus, also known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). It has spread globally since with more than 2 million cases reported as of April 2020(1), (2). Severe hypoxemic respiratory failure is by far the most common reason for admission to intensive care units due to Coronavirus disease 2019 (COVID-19). In a report from Lombardi, Italy, of 1591 critically ill COVID-19 patients, 99% required respiratory support of at least supplemental oxygen and 88% (or 1150 patients) required invasive ventilation.(3) Another retrospective review of Wuhan hospitalized patients, including non-COVID-19 patients, showed 52% required respiratory support, of which 55% needed mechanical ventilation (4). Mortality of COVID-19 patients on invasive ventilation has been reported to be greater than 90% in Italy, China and New York. (3-5)

High flow nasal therapy (HFNT) is a non-invasive oxygen delivery system that allows for administration of humidified air-oxygen blends as high as 60 liters per minute and a titratable fraction of inspired oxygen as high as 100%. HFNT has shown effectiveness in other severe viral respiratory illnesses like influenza A and H1N1(6). Use of HFNT has led to lower progression to invasive ventilation compared to other forms of noninvasive oxygen therapy (7-9). By decreasing the incidence of invasive ventilation, HFNT has the potential advantage of theoretically decreasing the incidence of ventilator-associated pneumonia (VAP), as well as reduction in hospital resources which can be critical during times of increasing strain on the healthcare system. When compared with noninvasive positive pressure ventilation (NPPV), the use of HFNT is associated with similar rates of reintubation due to post-extubation respiratory failure. (10) However, no short-term mortality benefit has been reported using HFNT to treat acute hypoxemic respiratory failure. (7, 11, 12).

The Surviving Sepsis Guidelines for COVID-19 recommends using HFNT in patients with acute hypoxemic respiratory failure due to COVID-19 (13). However, others recommend against using HFNT fearing that it will create aerosolization of the COVID-19 virus and increase transmission to healthcare providers (14-16). In the few case series that report HFNT use in COVID-19 patients, its usage has ranged from 4.8 - 63.5% (17-20). In a recent report of patients who succumbed to COVID-19 in China, 34.5% were placed on HFNT alone; the authors postulated that use of HFNT may have contributed to a delay in intubation thereby increasing mortality (21).

Herein we present a retrospective analysis of the outcomes of COVID-19 patients with moderate-to-severe hypoxemic respiratory failure receiving HFNT at our center.

Methods

The study was approved by the Temple University Institutional Review Board (TUIRB protocol number: 27051). A waiver of consent was granted due to the acknowledged minimal risk to the patients.

Design

This was a retrospective analysis of consecutive patients admitted to Temple University Hospital in Philadelphia, Pennsylvania, from March 10, 2020, to April 24, 2020, for moderate to severe hypoxemia due to highly suspected or proven COVID-19 infection. Patients who presented to our hospital with fever or acute respiratory symptoms of unknown etiology were screened for COVID-19 infection. Patients included in analysis were those that tested positive for COVID-19 using nasopharyngeal real time reverse transcriptase PCR (RT-PCR) or patients with high clinical suspicion and findings suggestive of COVID-19 based on high-resolution computerized tomography (HRCT) of the chest (typical peripheral nodular or ground glass opacities without alternative cause (22, 23) with typical inflammatory biomarker profile.

Data including demographics, age, sex, comorbidities, body mass index (BMI), smoking status (current smoker, non-smoker), admission laboratory data including complete blood count (CBC) with differential, ferritin, lactate dehydrogenase (LDH), d-dimer, and C-reactive protein (CRP), treatments offered were collected for all of these patients. We also collected oxygen saturation to fraction of inspired oxygen ratio (SF ratio) on day of HFNT initiation, at day 7 after HFNT initiation or at discharge, whichever came earlier. SF was used as a surrogate for PF ratio (partial pressure of Oxygen/fraction of inspired Oxygen) as they have been correlated well in clinical trials (24).

5

Radiology

Chest Radiographs (CXR) were graded by senior pulmonary and critical care fellows according to the RALES grading system (see Figure 1) previously studied in ARDS and organ donors (25). Chest X-rays were graded on the day of initiation of HFNT and earlier of discharge day or day 7.

Respiratory therapy

All patients included in the analysis had moderate to severe hypoxemic respiratory failure and were on oxygen delivery via HFNT during the hospital course. Receipt of any other form of respiratory support initially was considered as exclusion criteria for the study. HFNT was provided with a humidified air-oxygen blend starting at 35 lpm with the fraction of inspired oxygen (F_1O_2) adjusted to maintain oxygen saturations \geq 94%; further adjustments were made based on patients' tolerance and goals of oxygenation. The initial temperature for the high flow setup was 37° C and was titrated between 34-37° C for patient comfort. Data on initial oxygenation support were collected which included the flow of air-oxygen blend in liters per minute and fractional percentage of inspired oxygen.

Outcomes

Our primary outcome was the prevention of invasive mechanical ventilation (IMV) (%) with use of HFNT. Our secondary outcomes were mortality, change in oxygen saturation to fraction of inspired oxygen ratio (S-F ratio), change in RALE score of CXR, hospital length of stay (LOS) and hospital/ventilator acquired pneumonia. Hospital and ventilator acquired pneumonia was defined based on the presence of sputum positivity and treatment with antibiotics. Changes in S-F ratio were calculated by difference between S-F ratio at day 7 or discharge (whichever was earlier) versus day 1.

HFNT patients were divided into two groups: 1) progression to IMV (i.e., intubation group) and 2) continued HFNT support (i.e., non-intubation group). Patients who required NPPV are

reported in the non-intubation group. Comparison was made between demographics, baseline laboratory values, and outcomes within the two groups. Improvements/worsening in oxygenation at day 7 and change in clinical parameters of heart (HR) and respiratory rates (RR) were also analyzed.

We constructed a prediction model for intubation for our cohort. All comorbidities, demographics, clinical and laboratory data were used to investigate parameters that could predict need for intubation. A cumulative comorbidity score (1 point allocated for each of the 5 comorbidities reported) and cumulative inflammatory laboratory marker score (1 point for each abnormal lab) were tested as predictors of intubation.

Statistical methods

Continuous variables are presented as means (± standard deviation), and categorical variables as numbers and Frequency (percentages). Continuous variables were compared with the use of the two-sample t-test or paired t-test for categorical variables with the use of the Pearson chi-square test. Laboratory data were nonparametric and compared using Wilcox Rank-Sum test. Kaplan-Meier analysis was estimated for survival and compared by log-rank test.

To build a predictive model of the intubation, multivariable logistic regression was performed to determine the adjusted associations of the variables with intubation. The initial model included all the variables associated with intubation in univariate analyses for p<0.1. The final model that optimized the balance of the fewest variables with good predictive performance. Assessment of model performance was based on discrimination and calibration. Discrimination was evaluated using the C-statistic, which represents the area under the receiver operating characteristic (ROC) curve, where higher values represent better discrimination. Calibration was assessed by the Hosmer-Lemeshow test, where a p-value greater than 0.05 indicates adequate calibration.

All statistical tests were two-tailed, and P values of less than 0.05 were considered to indicate statistical significance. All statistical analyses were performed with the use of Stata 14.0 (StataCorp LP, College Station, TX).

Results

Patient population

894 patients admitted to Temple University Hospital between March 10, 2020, and April 24, 2020 who had suspected COVID-19 infection were retrospectively screened for our study. 445 patients had tested positive for COVID-19 by nasopharyngeal RT-PCR or were treated for high clinical suspicion based on typical CT imaging and inflammatory biomarker profile.

Of the 445 patients, 353 patients had hypoxemic respiratory failure requiring some form of oxygen therapy. The level of oxygen ranged from 2 L/min of oxygen via simple Nasal cannula to requiring invasive mechanical ventilation requiring positive pressure and 100% oxygen. 104 (23.3% of all COVID-19 positive patients) met our inclusion criteria of having moderate to severe COVID-19 related hypoxemic respiratory failure and were treated with HFNT (figure 2). The reported hypoxemia was moderate to severe with mean S-F ratio of 121.9 (range 79-225). Higher Chest Xray RALE scores were associated with more severe S-F ratios.

The average age was 60.66 (±13.50) years, 49 (47.12 %) were female, 53 (50.96%) were African American, 23 (22.12%) Hispanic. Forty-three patients (43.43%) were smokers. The major comorbidities reported (in descending incidence) were hypertension, diabetes, lung disease, heart disease and chronic kidney disease (CKD) (Table 1). Nine (9.78%) patients were also on hemodialysis. Baseline S-F ratios were severely low at 121.9, corresponding to a P-F ratio of ~100. Elevated inflammatory markers (i.e., ferritin, CRP, D-dimer, fibrinogen, LDH,

IL-6), creatinine along with transaminitis and lymphopenia were observed in all patients. In terms of treatments, azithromycin (57.2%) and steroids (64.71%) were the most frequently used therapies. Immunomodulators like sarilumab, anakinra, IVIG and tocilizumab were the next most commonly used therapies.

High Flow Details

104 (23.3%) of 445 COVID positive patients required HFNT support. Initial HFNT settings were 31.8 (±9.17) L/min of flow, while fractional of inspired oxygen (FiO2) was 90% (±16.7). The average use of HFNT for our population was 4.58 days (±3.28). The minimum settings on HFNT were 10 L flow and FiO2 of 30%, while the maximum settings were 60 L and FiO2 of 100%. Forty-five (43.2%) of patients receiving HFNT progressed to IMV or NPPV. The incidence of hospital associated pneumonia on HFNT was 2.94%. Two patients were excluded from analysis due to short follow-up.

Use of High-Flow for liberation from Mechanical ventilation (IMV+NIPPV)

11 of the IMV patients were successfully extubated to High flow with no re-intubations in this subgroup. Six of the eight patients on NPPV were successfully liberated from NPPV with the use of HFNT.

Outcomes

The SF ratio significantly improved from 123.5 to 234.5 from day 1 to day 7. Chest X-ray score improved from 18.17 to 16.13 (p < 0.0001), heart rate decreased from 88.2 (\pm 17.13) to 75.7 (\pm 23.13) (p = 0.004) and respiratory rate improved from 29.71 (\pm 18.99) to 26.38 (\pm 16.93) (p = 0.0001) (Table 2). Sixty seven of 104 (64.42%) were able to avoid invasive mechanical ventilation in our cohort. Overall, 45 patients required mechanical ventilation, of which 37

(35.58%) required IMV and 8 patients (7.69 %) required non-invasive positive pressure ventilation (NPPV).

Overall, mortality was 14.44% (n=15) in our cohort with 13 (34.4%) in the intubation group and 2 (2.9%) in the non-intubation group. Both the deaths in the non-intubation group were patients transitioned to comfort-directed care. Lastly, 10 of the 13 deaths were related to non-pulmonary organ failure and complications (table 3).

As of this writing, 48 patients from the HFNT group were discharged from the hospital with LOS 10.9 days (±6.04). ICU length of stay for the 38 patients discharged from ICU was 6.55 days (±5.31). ICU LOS was higher for the intubation group (10.45 days vs 4.05 days, p=0.0008).

Intubation versus non-intubation (continued HFNT) group.

The average duration of high flow use was higher in the non-intubation group. (5.38 days vs 3.11 days, P=0.0023). There were no statistically significant differences between the intubation and non-intubation groups in terms of demographics (age, sex, BMI, most comorbidities, smoking). Hypertension and smoking prevalence were higher in the intubation group. Amongst laboratory markers, D-dimer, LDH and Fibrinogen was higher in the non-intubation group while ferritin, triglycerides, IL-6, AST, BUN and creatinine were higher in the intubation group (table 4). SF ratios were significantly different between the two groups at baseline, with the intubation group having much lower SF ratios compared to those who remained on HFNT (111.03 vs 127.9, p=004). There was greater improvement in SF ratio and chest X-ray score (Figure 3) in the non-intubation group (Table 5). Patients in the intubation group had higher tocilizumab use, whereas Anakinra, IVIG and antibiotics were more common in the non-intubation group.

Mortality and incidence of Ventilator associated Pneumonia/Hospital acquired pneumonia was statistically higher in the intubation groups. Figure 4 shows better survival for the non-intubation group compared to the intubation group.

Prediction Model

In the univariate analysis, history of hypertension, chronic kidney disease (CKD) or having a composite comorbidity score of 1 or greater was predictive of progression to intubation. In terms of laboratory markers, elevated triglycerides (>300 mg/dl) and lower fibrinogen (<=450) were predictive in univariate analysis. S-F ratio <100 (OR = 2.3) was also a significant predictor in univariate analysis. In the multivariate analysis only S-F ratio (<100), history of chronic kidney disease and Fibrinogen (<450 mg/dl) were predictive of intubation (table 6). Figure 5 shows the ROC curve for our prediction model (ROC = 0.7229)

Discussion

In this retrospective review of patients with COVID-19 and acute hypoxemic respiratory failure we found that 104 patients (23.3%) were treated initially with HFNT, of which 64.4% remained on HFNT and were able to avoid escalation to non-invasive and invasive mechanical ventilation. The 67 non-intubation patients (continued HFNT therapy) had a significant improvement in oxygenation and reduction in incidence of hospital-acquired pneumonia compared to those who progressed to intubation or NPPV. While the survival advantage cannot be attributed to HFNT based on our study's retrospective design, use of HFNT did not result in worsened outcomes either. Majority of the patient mortality was attributed to the high burden of comorbidities (metastatic cancer, underlying renal and cardiac conditions, obesity, smoking and bacteremia), rather than progression of respiratory failure on HFNT (Table 5).

In similar patients in Italy and China, the intubation rate has been reported between 70-90%. (3, 20). In addition, our group also had a very high burden of comorbid disease, including underlying lung disease and tobacco use. Among our cohort of patients, 30.69% of patients had underlying lung disease and 43.43% were current smokers. In comparison, early case series reports from China only describe 1.1-3.1 % of patients with chronic obstructive pulmonary disease (COPD) (1, 4, 22), whereas case series from the Lombardy region of Italy reports 4% of patients with COPD (3). Bhatraju et al. reported only one patient with COPD in their recent case series of 21 patients from the Seattle region. (23) The rate of smokers in these studies was also low compared with our group's prevalence of 43.43%. There was no statistically significant difference in our group between those with and without underlying lung disease with regards to progression to invasive mechanical ventilation. In addition, Hypertension and CKD were also shown to be predictive of intubation in our univariate analysis, with CKD also a predictor in multivariate analysis. Chronic uremia in presence of hypertension leads to chronic left ventricular hypertrophy and other structural changes to the myocardium leaving the patients vulnerable to very small amounts of fluid shifts; subsequently leading to pulmonary edema. (24) CKD has also previously been shown to have worse outcomes including mortality in patients diagnosed with pneumonia.(25) A fibrinogen level of less than 450 mg/dL was found to be predictive of intubation in both univariate and multivariate analysis, fibrinogen is an acute phase reactant and it is possible that patients that present with a fibrinogen <450 mg/dL may be presenting in a later stage of disease and less amenable to antiviral or anti-inflammatory therapies during support with HFNT

Prevention of avoidable invasive mechanical ventilation with HFNT is significant as by nature it avoids incidence of ventilator-associated pneumonia, reduces the need to use medications such as sedatives in which shortages are being reported in the current public health crisis (26, 27). The reported mortality in patients requiring invasive mechanical ventilation in COVID-19 is 90%

(3, 4, 20). Our study shows mortality to be much lower when IMV can be avoided. In addition, HFNT can also decrease utilization of ventilators, sedatives in the setting of a global pandemic; thus, representing a viable alternative to IMV.

Gattinoni and colleagues have previously reported high respiratory compliance despite a large shunt fraction (28), proposing that COVID-19 patients fall into two groups. The "Type L" or "non-ARDS Type 1" phenotype have low elastance/high compliance and possible loss of hypoxic vasoconstriction mechanisms and often present with profound hypoxemia and low lung recruitability. The "Type H" or "ARDS Type 2" phenotype has increased pulmonary edema and progression to consolidation and requires traditional management strategies of higher PEEP and lower tidal volumes (29). We have experienced similar patient subgroups in our practice. As HFNT only provides a modest PEEP effect (i.e. 3-5 cmH₂O at flow rates of 30-50 lpm with mouth closed) (30) patients with predominant Type L physiology who do not require the higher positive pressure benefit from the oxygenation support that HFNC can provide noninvasively. HFNT can lead to a high oxygen reservoir by reducing anatomical dead space in the nasopharynx (31). Furthermore, IMV using high tidal volume (which is often employed in Type L patients) has shown to have inflammatory cytokine release in ARDS patients, including IL-6, both in critically ill humans (32, 33) and murine models (34, 35); IL-6 in particular is one of the pathologic mechanisms for lung injury in COVID-19 (36, 37). Thus, use of HFNT should be a priority in patients with severe COVID-19 respiratory failure.

We elected to use SF ratio than traditional PF ratios in this study for several reasons. SF ratios have been well correlated to standard PF ratios in adult and pediatric populations (38, 39). SF ratios < 235 predict moderate-severe respiratory failure with 85% specificity (39). Our cohort overall showed moderate to severe hypoxemic respiratory failure (mean SF ratio 123 overall), but nonetheless ~64.4 % of our cohort could still be supported with high flow oxygen alone. In contrast, Wang et.al showed only 37% of COVID-19 patients did not progress on HFNT when

the P-F ratio was less than 200(40). Additionally, lab draws, and arterial blood gases were limited during a pandemic to minimize staff exposure when possible. Hence, ABGs were not routinely collected as part of standard clinical practice at our institution

There has been debate worldwide about the use of HNFT or other methods of non-invasive ventilation out of concerns for increased disease transmission. During the 2003 SARS outbreak, hospital workers had development of SARS in only 8% of HFNT patients. (41) Studies have not shown that bacterial environmental contamination was increased in the setting of HFNT use (13, 14, 42). An in-vitro study mimicking clinical scenarios including HFNT with mannequins only revealed proximal dispersion of secretions to the face and nasal cannula itself.(43, 44) A recent study with healthy volunteers wearing high-flow nasal cannulas at both 30 L/min and 60 L/min of gas flow did not report variable aerosolization of particles between 10-10,000 nm, regardless of coughing, when compared with patients on room air or oxygen via regular nasal cannula.(45)

This study has several limitations. First, it was retrospective in nature as developing a prospective trial on the initial management of acute hypoxemic respiratory failure in the face of an evolving public health crisis is difficult. Second, we could not reasonably analyze a control arm as our endpoint was prevention of mechanical ventilation. Developing a prospective study during a pandemic situation is impractical without first determining clinical equipoise. Third, we do not report on arterial pH or partial pressure of carbon dioxide (PaCO₂) as many patients did not have baseline or follow up arterial blood gas measurements prior to initiation of HFNT. We recognize that in many clinical trials an elevated PaCO2 was an exclusion criterion for enrollment. (7, 10) Fourth, our data on hospital length of stay was limited since several patients were still hospitalized at the time data was collected.

Institutions around the world have been skeptical about the use of HFNT in CVOID-19 patients. However, based on our findings, we conclude that there is a role for high flow nasal therapy in patients with COVID-19 related severe respiratory failure especially the L-phenotype. Use of HFNT can not only reduce intubation rates, but also has the potential to reduce mortality and morbidity associated with it.

Figure 1: Radiographic Assessment of Lung Edema (RALE) grading system for Chest X Ray

Figure 2: Flow chart demonstrating screening for our patients

Figure 3: Progression of Chest imaging for patients on High Flow. Image A: Worsening bilateral infiltrates in Intubation group Image B: Non-intubation group, improved infiltrates

Figure 4: Kaplan Meir estimate of survival of HFNT patients, comparing intubation versus non-intubation (continued HFNT) groups

Figure 5: ROC curve of the predictive model for intubation

Table 1: Demographics data including laboratory and clinical parameters

Demographics	n = 104
Age (yrs., Mean <u>+</u> SD)	60.66 (<u>+</u> 13.50)
Sex (F) n (%)	49 (47.12 %)
BMI* kg/m2 (Mean <u>+</u> SD)	32.14 (<u>+</u> 7.80)
Comorbidities n(%)	
1. Diabetes	35 (34.65%)
2. Hypertension	46 (45.10%)
3. Lung Dx	31 (30.69%)
4. Heart Dx	23 (22.55%)
5. CKD	15 (16.3%), 9 (9.78%) on HD
Race	
African American	53 (50.96%)
2. Hispanic	23 (22.12%)

r	
3. Caucasian	9 (8.65%)
4. Other	4 (3.85%)
5. Unknown	15 (14.42%)
Smoking n (%)	
No	51 (51.52%)
Yes	43 (43.43%)
	(,
Initial Vitals	
Heart rate (Mean <u>+</u> SD)	98.0(<u>+</u> 20.17)
Respiratory Rate (Mean <u>+</u> SD)	22.03 (<u>+</u> 5.47)
Temperature (Mean <u>+</u> SD)	99.4 (<u>+</u> 2.18)
Pulse Oximetry (Mean <u>+</u> SD)	89.9 (<u>+</u> 10.09)
Laboratory Abnormalities	
Mean <u>(+</u> SD)	
Ferritin (ng/ml)	1216.0(<u>+</u> 2790.6)
CRP* (mg/dl)	11.77(<u>+</u> 8.38)
LDH* (U/L)	452.06 (<u>+</u> 292.36)
D-Dimer (ng/ml)	5659.6(<u>+</u> 17267.49)
Fibrinogen (mg/dl)	490.23(<u>+</u> 178.44)
Lymphocyte Count (K/mm^3)	1.02 (<u>+</u> 0.54)
IL-6* (pg/ml)	82.5 (<u>+</u> 149.54)
AST* (U/L)	56.8(<u>+</u> 74.90)
ALT* (U/L)	38.6 (<u>+</u> 31.93)
Platelets (k/mm3)	221.7(<u>+</u> 106.19)

Triglycerides	186.7(<u>+</u> 253.78)
BUN* (mg/dl)	28.4 (<u>+</u> 24.07)
Creatinine (mg/dl)	2.61(<u>+</u> 3.95)
Treatments	
Remdesivir	9 (9.68%)
Sarilumab	40 (39.22%)
Anakinra	12 (11.76%)
Tocilizumab	6 (5.88%)
Etoposide	1 (0.97%)
IVIG	19(18.63%)
Pulse Steroids	66 (64.71%)
Hydroxychloroquine	22 (21.57%)
Azithromycin	59 (57.2%)
Antibiotics	76 (73.08%)

Table 2: Outcomes of patients treated with HFNT

Outcomes	Total (n = 104)	P-value
Prevention of intubation	67 (64.42%)	
Intubation Rate	37 (35.58%)	
Mortality	14.44%	

Hospital Length of stay (LOS)	10.96 days (<u>+</u> 6.04)		
ICU length of Stay	6.55 days (<u>+</u> 5.31)		
HAP/VAP incidence	3 (2.94%)		
	Day 0	Day 7-10	
SF Ratio	121.9(<u>+</u> 41.02)	234.5(<u>+</u> 120.79)	< 0.0001
CXR Rale Score	18.17 (<u>+</u> 7.87)	16.13 (<u>+</u> 8.79)	0.0018
Heart Rate (beats per			
minute)	88.2 (<u>+</u> 17.13)	75.7 (<u>+</u> 23.13)	0.0004
Respiratory rate			
(breaths/min)	29.71 (<u>+</u> 18.99)	26.38 (<u>+</u> 16.93)	0.0001

Table 3: Clinical descriptors of deceased patients in our COVID19/HFNT cohort

	Age	Comorbidities	ВМІ	Complications
Patient 1	90	HTN, Diabetes, PE, HFpEF	36.4	Family opted for comfort/Hospice care
Patient 2	78	Stage 5 CKD, HTN, Metastatic prostate cancer	29	Patient had a prolonged stay on the ventilator with failure to wean off the vent. Acute on Chronic Renal failure requiring Dialysis Family decided to opt for comfort/Hospice.

Patient 3	70	OSA, Asthma, ILD,	41	Heart failure exacerbation
		severe PH, HFrEF,		Family opted for comfort/Hospice care
				Tarring opted for connectificapiec care
		Diabetes, HTN, CAD,		
		aortic stenosis		
Patient 4	65	HFrEF with AICD,	32.4	Heart failure exacerbation
		Afib, Diabetes, HTN,		Renal failure requiring Dialysis
		CKD, BRASH		Ascites requiring Paracentesis
		syndrome,		Invasive mechanical ventilation
		Congestive hepatic		
		failure		
Patient 5	75	Left lung transplant,	20.3	Superimposed klebsiella pneumonia
		Severe COPD,		Invasive mechanical ventilation
		Benign pleural		Acute kidney injury
		asbestosis, chronic		
		hypoxemic respiratory		
		failure		
Patient 6	56	Chronic hypoxic	39.5	Acute renal failure with hyperkalemia
		respiratory failure,		Invasive mechanical ventilation
		COPD, OSA, HTN,		
		seizure disorder		
Patient 7	76	HTN, arthritis	33.6	Acute kidney injury with metabolic acidosis and
				hyperkalemia
				Invasive mechanical ventilation
				invasive meenamear ventulation

				Hypercapnic respiratory failure
Patient 8	46	ESRD on HD, morbid obesity, HTN, HLD, T2DM, former smoker, Chronic Bronchitis, hepatitis B	35	Invasive mechanical ventilation Septic shock from staphylococcus bacteremia Acute pulmonary embolism Heparin induced thrombocytopenia Hemophagocytic Lymphohistiocytosis (HLH)
Patient 9	59	HTN Glaucoma	21.93	Invasive mechanical ventilation Acute arterial thrombosis of left common illac artery Compartment syndrome requiring fasciotomy Acute renal failure Non-ST elevation myocardial infarction
Patient 10	69	HFpEF, Aortic Stenosis, COPD on home oxygen, Renal transplant with graft failure, ESRD on HD, DVT, CVA, T2DM, HTN, OSA	28.17	Pulmonary edema requiring emergent ultrafiltration Invasive Mechanical ventilation
Patient 11	66	HTN, HLD, Stage III CKD, current smoker	27.3	Invasive Mechanical ventilation Acute Pulmonary embolism Acute kidney injury requiring HD

Patient 12	67	Hypertension,CKD	30.45	Tracheostomy
		Diabetes, Sacral		Invasive Mechanical Ventilation
		decubitus ulcers		Delirium
		decubitus dicers		
				Ventricular tachycardia
				Acute renal failure
Patient 13	73	Lung transplant,	27.08	Invasive Mechanical Ventilation
		Pulmonary fibrosis,		DVT
		HTN, Atrial fibrillation,		Acute kidney injury
		CAD with cardiac		Heparin induced thrombocytopenia
		bypass surgery		
Patient 14	50	HFrEF40-45%, Renal	50	Septic shock from staphylococcus epidermidis bacteremia
		Transplant with failed		Heparin induced thrombocytopenia
		graft, HD, breast		Cardiac arrhythmias
		cancer s/p		
		mastectomy, DM,		
		HTN		
Patient 15	41	bipolar disorder,	37.12	New Renal Cell carcinoma with Metastasis
		endometrial		Acute respiratory distress syndrome.
		adenocarcinoma s/p		
		hysterectomy/salping		
		ectomy		

*HTN - hypertension, PE- pulmonary embolism, HFpEF- Heart failure with preserved Ejection fraction, CKD - chronic kidney disease, OSA- Obstructive sleep apnea, ILD-interstitial lung disease, PH- pulmonary hypertension, HFrEF - heart failure with reduced Ejection fraction, CAD - coronary artery disease, COPD- chronic obstructive pulmonary disease, ESRD - End stage renal disease, HD- hemodialysis, DVT- deep venous thrombosis, CVA - cerebrovascular accident

Table 4: Comparing demographics data between intubation and non-progression groups.

Demographics	intubation (n =37)	Non-	P-value
		intubation(n=67)	
Age (yrs, Mean <u>+</u> SD)	63.9 (<u>+</u> 11.67)	58.9 (<u>+</u> 14.17)	0.06
Sex (F) n (%)	16 (43.24 %)	33 (49.25 %)	0.55
BMI* kg/m2 (Mean <u>+</u> SD)	31.0 (<u>+</u> 6.74)	32.8 (<u>+</u> 8.33)	0.27
Comorbidities n (%)			
1. Diabetes	12 (33.33%)	23 (35.38%)	0.84
2. Hypertension	21 (56.76%)	25(38.46%)	0.07
3. Lung Dx	14 (38.89%)	17 (26.15%)	0.18
4. Heart Dx	10 (27.03%)	13 (20.00%)	0.41
5. CKD	7 (21.21%)	8 (13.56%)	0.34
6. Chronic	4 (12.12%)	5 (8.47%)	0.57
Hemodialysis			
Race			

African American	18 (48.65%)	35 (52.24%)	
2. Hispanic	8 (21.62%)	15 (22.62%)	0.192
3. Caucasian	6 (16.22%)	3 (4.48%)	
4. Other	0	4 (5.97%)	
5. Unknown	5 (13.51%)	10 (14.93%)	
Smoking^ n(%)			
No	15 (41.67%)	36 (57.14%)	0.19
Yes	18 (50.00%)	25 (39.68%)	
Initial Vitals			
HR (Mean <u>+</u> SD)	97.32 (<u>+</u> 21.98)	98.3 (<u>+</u> 19.24)	0.80
RR (Mean <u>+</u> SD)	21.49 (<u>+</u> 6.11)	22.3 (<u>+</u> 5.09)	0.45
Temperature (Mean + SD)	99.2 (<u>+</u> 2.54)	99.6 (<u>+</u> 1.95)	0.36
Pulse Oximetry (Mean <u>+</u> SD)	89.2(<u>+</u> 12.30)	90.4 (<u>+</u> 8.67)	0.58
Laboratory Abnormalities			
Mean (<u>+</u> SD)			
Ferritin (ng/ml)	1078.2(<u>+</u> 1720.37)	1290.5(<u>+</u> 3236.69)	0.59
CRP* (mg/dl)	12.51 (<u>+</u> 10.02)	11.35(<u>+</u> 7.38)	0.90
LDH* (U/L)	444.51(<u>+</u> 322.57)	463.4 (<u>+</u> 244.33)	0.58
D-Dimer (ng/ml)	9241.76	3604.36	0.36
	(<u>+</u> 24519.18)	(<u>+</u> 10938.11)	
Fibrinogen (mg/dl)	430.9 (<u>+</u> 205.05)	523.64 (<u>+</u> 153.66)	0.009
Abs Lymph Ct* (K/mm^3)	1.05 (<u>+</u> 0.43)	1.00 (<u>+</u> 0.50)	0.39

	-	-	
IL-6* (pg/ml)	130.9(<u>+</u> 210.15)	42.6 (<u>+</u> 48.07)	0.12
AST* (U/L)	69.2 (<u>+</u> 112.06)	48.6(<u>+</u> 32.45)	0.90
ALT* (U/L)	39.78(<u>+</u> 43.54)	37.85(<u>+</u> 22.89)	0.51
Platelets (k/mm3)	215.2 (<u>+</u> 115.74)	225.5 (<u>+</u> 101.02)	0.60
Triglycerides (mg/dl)	293.96 (<u>+</u> 454.58)	145.26 (<u>+</u> 75.86)	0.52
BUN* (mg/dl)	31.95(<u>+</u> 21.86)	26.32 (<u>+</u> 25.24)	0.08
Creatinine (mg/dl)	2.88 (<u>+</u> 3.58)	2.46 (<u>+</u> 4.15)	0.09
Treatments			
Remdesivir trial^	5 (13.89%)	4 (7.02%)	0.27
Sarilumab trial^^	12 (33.33%)	28 (42.42%)	0.36
Anakinra	0	12 (18.18%)	0.006
Tocilizumab	5 (13.89%%)	1 (1.52%)	0.011
Etoposide	1 (2.70%)	0	0.18
IVIG	11 (30.56%)	8 (12.12%)	0.02
Pulse Steroids	26 (72.22%)	40 (60.61%)	0.24
Hydroxychloroquine	6 (16.67%)	16 (24.24%)	0.37
Azithromycin	12 (41.38%)	22(61.1%)	0.30
Antibiotics	24 (64.86%)	15 (22.39%)	0.16

*BMI - body mass index, CKD- Chronic Kidney disease, HD - hemodialysis, CRP =C-reactive protein, LDH - Lactate dehydrogenase, Abs Lymph ct- absolute lymphocyte count, IL-6 - interleukin 6, AST - Aspartate Aminotransferase, ALT - Alanine Aminotransferase, BUN - blood urea Nitrogen. ^smoking - current vs former/nonsmokers. ^NCT04292899 and NCT04292899. ^^NCT04315298

Table 5: Comparing outcomes between intubation and non-intubation groups.

Outcomes	Intubation	Non-intubation	P-value
Mortality	13 (35.1%)	2 (2.9%)	0.0018
Hospital LOS*			
(days)	13.67(<u>+</u> 7.97)	9.7(<u>+</u> 4.6)	0.03
ICU LOS			
(days)	10.45 (<u>+</u> 6.12)	4.05 (<u>+</u> 2.64)	0.0008
HAP/VAP incidence	3 (8.57%)	0	0.017
Change in SF Ratio	40.5 (<u>+</u> 67.90)	141.4 (<u>+</u> 117.14)	0.0001
Change in CXR Rale			
Score	-0.13(<u>+</u> 11.18)	-3.2(<u>+</u> 8.50)	0.09
Change in HR			
(beats/minute)	- 7.65 (<u>+</u> 20.69)	-7.95(<u>+</u> 19.19)	0.94
Change in RR			
(breaths/min)	-2.32 (<u>+</u> 9.32)	-4.4(<u>+</u> 8.39)	0.27

^{*}LOS - Length of stay, HAP/VAP - hospital acquired pneumonia/ventilator associated pneumonia, SF ratio - oxygen saturation/fraction of inspired oxygen, HR- heart rate, RR-respiratory rate

Table 6: Demographic, Clinical and laboratory predictors of Intubation using Multivariable Logistic regression

	Univariate	P-value	Multivariate	P-value
	Analysis (OR)		Analysis (OR)	
Age				
<= 65yrs	1			
> 65 yrs	1.5	0.31		
ВМІ				
<=30				
>30	0.79	0.57		
Gender				
Male				
Female				
Smoking				
No	1			
Yes	1.52	0.32		
Race				
Non-black	1			
Black	.87	0.72		
Comorbidities				
Heart Disease	1.48	0.41		
Lung Disease	1.79	0.19		

Diabetes		0.91	0.83		
HTN		2.1	0.07		
CKD		2.91	0.01	2.59	0.047
Hemodialysis	Hemodialysis		0.57		
No Comorbidi	ty	1			
Any comorbid	ity	3.51	0.03	2.7	0.11
Laboratory ma	arkers				
Ferritin	<400	1			
(ng/ml)	>=400	0.89	0.79		
D-dimer	<1000	1			
(ng/ml)	>=1000	1.47	0.37		
AST	<105	1			
(U/L)	>=105	1.6	0.53		
AST	<180	1			
(U/L)	>=180	0.29	0.26		
Triglycerides	<300	1			
(mg/dl)	>=300	4.81	0.07		
Fibrinogen	>450	1			
(mg/dl)	=<450	3.53	0.007	3.02	0.027
		1			

Abs Lymph	>=1	1	0.26		
(k.mm3)	<1	0.62			
LDH	<=350	1			
(U/L)	>350	1.85	0.18		
CRP	<6	1			
(mg/dl)	=>6	0.58	0.22		
Cumulative L	aboratory				
score (1 poin	t per				
abnormality)					
	<3	1			
	>=3	1.5	0.36		
S-F ratio	=>100	1			
	<100	2.3	0.05	2.61	0.04

Bibliography

- (1) Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, Du B, Li L, Zeng G, Yuen K, Chen R, Tang C, Wang T, Chen P, Xiang J, Li S, Wang J, Liang Z, Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J, Ye C, Zhu S, Zhong N. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* 2020;0:null.
- (2) COVID-19 Map; Johns Hopkins Coronavirus Resource Center. ;2020.
- (3) Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020.
- (4) Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-1062.
- (5) Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020.
- (6) Rello J, Pérez M, Roca O, Poulakou G, Souto J, Laborda C, Balcells J, Serra J, Masclans JR. High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v. *J Crit Care* 2012;27:434-439.
- (7) Frat J, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E,

Cottereau A, Devaquet J, Nseir S, Razazi K, Mira J, Argaud L, Chakarian J, Ricard J, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin J, Tonnelier J, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JM, Brochard L, Robert R. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 2015;372:2185-2196.

- (8) Ou X, Hua Y, Liu J, Gong C, Zhao W. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. *CMAJ* 2017;189:E260-E267.
- (9) Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, Mekontso-Dessap A, Schreiber A, Azoulay E, Mercat A, Demoule A, Lemiale V, Pesenti A, Riviello ED, Mauri T, Mancebo J, Brochard L, Burns K. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis.

 Intensive Care Med 2019;45:563-572.
- (10) Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. *JAMA* 2016;316:1565-1574.
- (11) Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pène F, Kontar L, Bruneel F, Klouche K, Barbier F, Reignier J, Berrahil-Meksen L, Louis G, Constantin J, Mayaux J, Wallet F, Kouatchet A, Peigne V, Théodose I, Perez P, Girault C, Jaber S, Oziel J, Nyunga M, Terzi N, Bouadma L, Lebert C, Lautrette A, Bigé N, Raphalen J, Papazian L, Darmon M, Chevret S, Demoule A. Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial. *JAMA* 2018;320:2099-2107.
- (12) Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer PR, van de Louw A, Hemelaar P, Lemiale V, Taccone FS, Martin Loeches I, Meyhoff TS, Salluh J, Schellongowski P, Rusinova

- K, Terzi N, Mehta S, Antonelli M, Kouatchet A, Barratt-Due A, Valkonen M, Landburg PP, Bruneel F, Bukan RB, Pène F, Metaxa V, Moreau AS, Souppart V, Burghi G, Girault C, Silva UVA, Montini L, Barbier F, Nielsen LB, Gaborit B, Mokart D, Chevret S. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. *Intensive Care Med* 2017;43:1808-1819.
- (13) Alhazzani W, Møller M, Arabi Y, Loeb M, Gong M, Fan E, Oczkowski S, Levy M, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow D, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan J, Kesecioglu J, McGeer A, Mermel L, Mammen M, Alexander P, Arrington A, Centofanti J, Citerio G, Baw B, Memish Z, Hammond N, Hayden F, Evans L, Rhodes A. Surviving Sepsis Campaign: Guidelines on the Management of Critically III Adults with Coronavirus Disease 2019 (COVID-19). *Critical Care Medicine* 2020:1.
- (14) Namendys-Silva SA. Respiratory support for patients with COVID-19 infection. *The Lancet Respiratory Medicine* 2020;8:e18.
- (15) Yu C. Correspondence. British Journal of Surgery 2019;106:949.
- (16) Kluge S, Janssens U, Welte T, Weber-Carstens S, Marx G, Karagiannidis C. German recommendations for critically ill patients with COVID219. *Medizinische Klinik, Intensivmedizin und Notfallmedizin* 2020.
- (17) Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med* 2020.
- (18) Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and

Outcomes of 21 Critically III Patients With COVID-19 in Washington State. JAMA 2020.

- (19) Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020.
- (20) Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine* 2020.
- (21) Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. *JAMA network open* 2020;3:e205619.
- (22) Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, Zhang Z, Guan W, Ling Z, Jiang R, Hu T, Ding Y, Lin L, Gan Q, Luo L, Tang X, Liu J. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur J Nucl Med Mol Imaging* 2020;47:1275-1280.
- (23) Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA, West TE, Luks A, Gerbino A, Dale CR, Goldman JD, O'Mahony S, Mikacenic C. Covid-19 in Critically III Patients in the Seattle Region Case Series. *New England Journal of Medicine* 2020;0:null.
- (24) Jp K, Km L. Cardiovascular aspects in renal disease. *Curr Opin Nephrol Hypertens* 1993;2:791-797.
- (25) Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, Manresa F, Dorca J, Gudiol F, Carratalà J. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. *Nephrol Dial Transplant* 2011;26:2899-2906.
- (26) A new Covid-19 problem: Shortages of medicines needed for placing patients on ventilators Kneecap Our Medical System. 2020.

- (27) Choo EK, Rajkumar SV. Medication Shortages During the COVID-19 Crisis: What We Must Do. *Mayo Clinic Proceedings* 2020;0.
- (28) Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. *American journal of respiratory and critical care medicine* 2020.
- (29) Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Medicine* 2020.
- (30) Parke RL, McGuinness SP. Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. *Respir Care* 2013;58:1621-1624.
- (31) Spence C, Spence C, Buchmann N, Buchmann N, Jermy M, Jermy M. Unsteady flow in the nasal cavity with high flow therapy measured by stereoscopic PIV. *Exp Fluids* 2012;52:569-579.
- (32) The Acute Respiratory Distress Syndrome Network. Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. *The New England Journal of Medicine* 2000;342:1301-1308.
- (33) Wrigge H, Zinserling J, Stüber F, Spiegel Tv, Hering R, Wetegrove S, Hoeft A, Putensen C. Effects of Mechanical Ventilation on Release of Cytokines into Systemic Circulation in Patients with Normal Pulmonary Function. *Anesthesiology* 2000;93:1413-1417.
- (34) Chiumello D, Valente Barbas CS, Pelosi P. Pathophysiology of ARDS. In: Lucangelo U, Pelosi P, Zin WA and Aliverti A, editors. Respiratory System and Artificial Ventilation. Milano: Springer Milan; 2008. p. 101-117.
- (35) Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. In: Pinsky MR, Brochard L and Mancebo J, editors. Applied Physiology in Intensive Care Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006. p. 357-366.
- (36) Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R,

- Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395:497-506.
- (37) Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? Journal of Translational Medicine 2020;18.
- (38) Nava S, Schreiber A, Domenighetti G. Noninvasive Ventilation for Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome. *Respiratory care* 2011;56:1583-1588.
- (39) Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. *Chest* 2007;132:410-417.
- (40) Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. *Annals of Intensive Care* 2020;10:37.
- (41) Raboud J, Shigayeva A, McGeer A, Bontovics E, Chapman M, Gravel D, Henry B, Lapinsky S, Loeb M, McDonald LC, Ofner M, Paton S, Reynolds D, Scales D, Shen S, Simor A, Stewart T, Vearncombe M, Zoutman D, Green K. Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada. *PLoS One* 2010;5.
- (42) Leung CCH, Joynt GM, Gomersall CD, Wong WT, Lee A, Ling L, Chan PKS, Lui PCW, Tsoi PCY, Ling CM, Hui M. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. *Journal of Hospital Infection* 2019;101:84-87.
- (43) Kotoda M, Hishiyama S, Mitsui K, Tanikawa T, Morikawa S, Takamino A, Matsukawa T. Assessment of the potential for pathogen dispersal during high-flow nasal therapy. *Journal of Hospital Infection* 2020;104:534-537.
- (44) Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bioaerosol dispersion. *Eur Respir J* 2020:2000892.

(45) Iwashyna TJ, Boehman A, Capelcelatro J, Cohn AM, Cooke JM, Costa DK, Eakin RM, Prescott HC, Woolridge MS. Variation in Aerosol Production Across Oxygen Delivery Devices in Spontaneously Breathing Human Subjects. *medRxiv* 2020:2020.04.15.20066688.

RALES S	CORING SYSTEM KEY			
Consc	olidation Score (C)		1	
Score	Extent of alveolar opacities			
0	None		1	
1 <25%			1	
2 25-50%		e: ·		
3 50-75%		Final	l Score	
4	>75%	Right Lung	Left Lung	
Density Score (D)		Upper Quadrant (Q1)	Upper Quadrant (Q3)	
Score	Score Density of alveolar opacities		C3 x D3 = Q3	
1	Hazy	Lower Quadrant (Q2)	Lower Quadrant (Q4)	
2	Moderate	C2 x D2 = Q2	C4 x D4 = Q4	
3 Dense		Total Score = Q1 + Q2 + Q3 + Q4		







